The U.S. Centers for Disease Control and Prevention issued a Level 1 global travel notice for dengue fever on March 23, 2026, alerting Americans to higher-than-usual activity in 16 countries where U.S. travelers have contracted the virus at unexpectedly elevated rates. The advisory covers Colombia, Samoa, Cook Islands, Bangladesh, Mali, Cuba, Sudan, Vietnam, Afghanistan, Mauritania, Pakistan, New Caledonia, Timor-Leste, Guyana, Maldives, and Bolivia.

A Level 1 alert — the lowest of four tiers in the CDC's travel health notice system — calls for travelers to "practice usual precautions," meaning basic mosquito-bite prevention rather than a recommendation to avoid travel. But public health officials warn that the underlying virus is anything but mild for a significant share of those infected.

What Dengue Actually Does

Dengue fever is caused by any of four closely related virus serotypes (DENV-1 through DENV-4), all transmitted by the Aedes aegypti mosquito. According to CDC, between 40 and 80 percent of infections produce no symptoms at all. Those who do develop illness typically experience fever, severe headache, muscle and joint pain, and skin rash within five to seven days of infection.

The danger lies in the minority of cases that progress to severe dengue. In those patients, the disease triggers hemorrhage — uncontrolled internal bleeding, including in the brain — along with respiratory distress, shock from a rapid drop in blood pressure, and organ failure, particularly of the liver, brain, and heart. Dengue shock syndrome, where catastrophic blood loss drives the body into circulatory collapse, is a recognized medical emergency requiring immediate hospitalization.

There is no specific antiviral treatment for dengue. Care consists of fluid management, blood pressure monitoring, and, in severe cases, transfusion to replace lost blood. A three-dose vaccine (Dengvaxia) is available and recommended for children aged nine to sixteen who have had a prior confirmed dengue infection, according to CDC — the vaccine can actually worsen outcomes in people who have never been infected before. No broadly available adult or traveler dengue vaccine exists.

Children under five, adults over 65, and pregnant women face the highest risk of severe disease.

The Numbers Behind the Warning

The advisory is set against a backdrop of massive global dengue activity in recent years. In 2024, the Americas alone recorded more than 13 million cases — a record high, according to CDC's outbreak tracking page. The year 2025 saw a significant decline from that peak, but the toll remained substantial.

According to PAHO's February 20, 2026 epidemiological update, the Americas reported a total of 4,459,521 suspected dengue cases and 1,682,588 confirmed cases in 2025. Of those, 8,966 were classified as severe dengue, and 2,207 people died, yielding a case fatality rate of 0.05 percent. PAHO noted the 2025 figures represented a 66 percent decrease in cases and a 74 percent reduction in deaths compared with 2024.

All four dengue virus serotypes circulated simultaneously in 2025, which PAHO flagged as a particular concern — simultaneous multi-serotype circulation increases the risk of severe outcomes, because prior exposure to one serotype can amplify the immune response to a second, sometimes fatally so.

By the end of January 2026 (epidemiological week 4), PAHO had recorded 122,090 cases across the Americas, including 22,409 laboratory-confirmed cases, 242 severe dengue cases, and six deaths — an 83 percent decrease in cases and a 98 percent reduction in deaths compared to the same period in 2025.

The European Centre for Disease Prevention and Control reported that as of the second week of 2026 (ending January 11), 69,772 cases had been reported in the Americas, of which 18 percent were laboratory-confirmed — 60 percent below the case count at the same point in 2025.

Samoa: A Prolonged Outbreak

One of the more acute situations flagged by the CDC advisory is Samoa, where a dengue outbreak that began in April 2025 has yet to resolve. As of early March 2026, the outbreak had produced 17,402 cumulative clinically diagnosed cases and 5,117 laboratory-confirmed cases, according to Outbreak News Today, citing Samoan health authority data. At least eight people have died, including a seven-month-old infant, according to reporting by the Daily Mail citing health officials.

Samoa has a population of approximately 220,000. An outbreak of that scale in a small island nation strains health system capacity and creates conditions for continued transmission.

The U.S. Domestic Picture

Dengue was effectively eliminated from the continental United States in the 1970s through mosquito control programs. Today, the continental U.S. does not have established endemic Aedes aegypti populations in most areas, meaning nearly all American cases are travel-linked.

In 2025, CDC recorded 67 locally acquired dengue cases in the U.S. — 60 in Florida, six in California, and one in Arizona — plus 1,128 travel-associated cases. So far in 2026, through mid-March, no locally acquired cases have been confirmed on the U.S. mainland, according to CDC's preliminary 2026 data. A total of 55 travel-associated cases have been detected, with Florida reporting the most at 16 cases, followed by New York with eight.

Florida's recurring local transmission status reflects the presence of Aedes aegypti mosquitoes in the southern part of the state — a population that emerged despite decades of suppression and has enabled sporadic local outbreaks when infected travelers arrive. Health officials treat Florida as the most likely vector for any future sustained domestic transmission.

What to Do If You're Traveling

CDC's current guidance for travelers heading to any of the 16 flagged countries is consistent with general mosquito-bite prevention recommendations: use EPA-registered insect repellents containing DEET, picaridin, IR3535, or oil of lemon eucalyptus; wear long-sleeved shirts and long pants; stay in air-conditioned accommodations or rooms with window screens; and use bed nets in areas without adequate screening.

Travelers who develop a fever above 100°F (38°C), severe headache, pain behind the eyes, joint or muscle pain, or any sign of bleeding — including bleeding gums, blood in urine or stool, or unusual bruising — within two weeks of returning from travel to a dengue-risk area should seek medical care immediately and inform their provider of their travel history. Early clinical recognition is critical; severe dengue can deteriorate within hours.

The Bigger Picture

Dengue's resurgence in recent years reflects a combination of factors: climate-driven expansion of Aedes aegypti habitat into higher latitudes and altitudes, rapid international travel, gaps in surveillance, and the immunological dynamics of multi-serotype circulation. The record 2024 outbreak was not an anomaly — it was a continuation of a decades-long trend line moving upward.

PAHO's February update explicitly recommended that countries maintain "integrated surveillance — epidemiological, clinical, laboratory, and entomological" and prioritize early clinical diagnosis and warning sign monitoring. The organization also called for countries to "adapt their health services as needed to ensure timely and quality care" and maintain lab capacity for early detection — language suggesting that at least some health systems in the region are already under strain.

The CDC advisory, while technically low-level, arrives as the Americas enter the spring and summer months when mosquito activity historically peaks. The combination of elevated baseline activity, multi-serotype circulation, and warm-season timing makes 2026 a year worth watching closely.